RCUS vs. STNE

Last updated Jun 4, 2026

RCUS (Arcus Biosciences, Inc.) and STNE (StoneCo Ltd.) are both stocks. RCUS operates in Biotechnology (Healthcare), while STNE operates in Software - Application (Technology). Over the past 5 years, RCUS returned -0.97%/yr vs -27.46%/yr for STNE. At a 0.25 correlation, their price movements are largely independent.

Performance

RCUS vs. STNE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcus Biosciences, Inc. (RCUS) and StoneCo Ltd. (STNE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, RCUS achieves a 0.13% return, which is significantly higher than STNE's -12.92% return.

RCUS

• 1D: -2.49%
• 1M: -8.41%
• YTD: 0.13%
• 6M: -6.91%
• 1Y: 137.89%
• 3Y*: 4.33%
• 5Y*: -0.97%
• 10Y*: —

STNE

• 1D: -5.34%
• 1M: -1.85%
• YTD: -12.92%
• 6M: -18.17%
• 1Y: -9.04%
• 3Y*: -0.28%
• 5Y*: -27.46%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

RCUS vs. STNE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
RCUS Arcus Biosciences, Inc.	0.13%	60.04%	-22.04%	-7.64%	-48.90%	55.89%	157.03%	-6.22%	7.38%
STNE StoneCo Ltd.	-12.92%	85.57%	-55.80%	91.00%	-44.01%	-79.91%	110.38%	116.32%	-41.18%

Correlation

The correlation between RCUS and STNE is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.21
Correlation (3Y) Calculated over the trailing 3-year period	0.22
Correlation (5Y) Calculated over the trailing 5-year period	0.29
Correlation (All Time) Calculated using the full available price history since Oct 26, 2018	0.25

Fundamentals

Market Cap RCUS : $2.99B STNE : $2.70B
EPS RCUS : -$3.31 STNE : $12.96
PS Ratio RCUS : 11.27 STNE : 0.24
PB Ratio RCUS : 5.71 STNE : 0.22
Total Revenue (TTM) RCUS : $236.00M STNE : $11.69B
Gross Profit (TTM) RCUS : $214.00M STNE : $8.11B
EBITDA (TTM) RCUS : -$341.00M STNE : $3.75B

Return for Risk

RCUS vs. STNE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RCUS

RCUS Risk / Return Rank: 88
RCUS Sharpe Ratio Rank: 90
RCUS Sortino Ratio Rank: 85
RCUS Omega Ratio Rank: 84
RCUS Calmar Ratio Rank: 91
RCUS Martin Ratio Rank: 90

STNE

STNE Risk / Return Rank: 33
STNE Sharpe Ratio Rank: 33
STNE Sortino Ratio Rank: 32
STNE Omega Ratio Rank: 32
STNE Calmar Ratio Rank: 33
STNE Martin Ratio Rank: 32

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RCUS vs. STNE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcus Biosciences, Inc. (RCUS) and StoneCo Ltd. (STNE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RCUS	STNE	Difference
Sharpe ratio Return per unit of total volatility	2.25	-0.18	+2.43
Sortino ratio Return per unit of downside risk	2.70	0.10	+2.60
Omega ratio Gain probability vs. loss probability	1.34	1.01	+0.33
Calmar ratio Return relative to maximum drawdown	4.99	-0.23	+5.22
Martin ratio Return relative to average drawdown	12.31	-0.47	+12.78
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RCUS vs. STNE - Sharpe Ratio Comparison

The current RCUS Sharpe Ratio is 2.25, which is higher than the STNE Sharpe Ratio of -0.18. The chart below compares the historical Sharpe Ratios of RCUS and STNE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	RCUS	STNE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.25	-0.18	+2.43
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.01	-0.42	+0.41
Sharpe Ratio (All Time) Calculated using the full available price history	0.06	-0.16	+0.22

Drawdowns

RCUS vs. STNE - Drawdown Comparison

The maximum RCUS drawdown since its inception was -85.83%, smaller than the maximum STNE drawdown of -92.31%. Use the drawdown chart below to compare losses from any high point for RCUS and STNE.

Drawdown Indicators

	RCUS	STNE	Difference
Max Drawdown Largest peak-to-trough decline	-85.83%	-92.31%	+6.48%
Max Drawdown (1Y) Largest decline over 1 year	-27.78%	-40.22%	+12.44%
Max Drawdown (3Y) Largest decline over 3 years	-70.82%	-57.64%	-13.18%
Max Drawdown (5Y) Largest decline over 5 years	-85.83%	-89.72%	+3.89%
Current Drawdown Current decline from peak	-50.77%	-86.31%	+35.54%
Average Drawdown Average peak-to-trough decline	-46.54%	-61.10%	+14.56%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.26%	19.35%	-8.09%

Volatility

RCUS vs. STNE - Volatility Comparison

The current volatility for Arcus Biosciences, Inc. (RCUS) is 12.17%, while StoneCo Ltd. (STNE) has a volatility of 15.62%. This indicates that RCUS experiences smaller price fluctuations and is considered to be less risky than STNE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RCUS	STNE	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.17%	15.62%	-3.45%
Volatility (6M) Calculated over the trailing 6-month period	46.19%	40.65%	+5.54%
Volatility (1Y) Calculated over the trailing 1-year period	62.22%	51.25%	+10.97%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	67.12%	64.89%	+2.23%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	76.34%	67.48%	+8.86%

Dividends

RCUS vs. STNE - Dividend Comparison

RCUS has not paid dividends to shareholders, while STNE's dividend yield for the trailing twelve months is around 23.78%.

Position	TTM
RCUS Arcus Biosciences, Inc.	0.00%
STNE StoneCo Ltd.	23.78%

Financials

Frequently Asked Questions

Can I hold both RCUS and STNE in my portfolio?

RCUS and STNE have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, RCUS or STNE?

STNE has higher volatility (15.62%) compared to RCUS (12.17%). In terms of maximum drawdown, RCUS dropped -85.83% vs STNE's -92.31%.

Which has better risk-adjusted returns?

RCUS currently has the higher Sharpe Ratio (2.25 vs -0.18), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.